March 16, 2012

HELIX BIOPHARMA CORP. ANNOUNCES Q2 2012 RESULTS (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical company developing drug
candidates for the prevention and treatment of cancer, confirmed that its Board of Directors has been reconstituted today, and announced its financial results and research and development update for the quarter ended January 31, 2012.